Skip to main content
. 2021 Jul 13;13(14):3498. doi: 10.3390/cancers13143498

Figure 1.

Figure 1

The BRAF→MEK1/2→ERK1/2 signaling pathway and FDA-approved targeted therapy. RAS-GDP to RAS-GTP exchange triggers a BRAF→MEK1/2→ERK1/2 phosphorylation cascade, resulting in metabolic reprograming, cell growth, proliferation, and differentiation. FDA-approved or fast-track-designated inhibitors targeting the MAPK components, as indicated.